Volition NuQ does use Elisa for testing and will be cheap to produce, perhaps comparable to our Colostat. USD$80 per test . Colostat is expected to cost AUD 90 per test. Volition is a capped at 100 million, near enough to 10 times our price. Much like Epigenomics, they are likely to miss FDA targets
for specificity and subsequently be rejected unless they're testing improves. I like NuQ but RHY offers much greater upside considering our enterprise value.
Ann: Final Antibody Selection Complete, page-16
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.033(25.4%) |
Mkt cap ! $15.41M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.0¢ | 9.7¢ | $114.8K | 1.082M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5500 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 164688 | 2 |
View Market Depth
| Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
| RHY (ASX) Chart |
